Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. This innovative approach targets a range of severe diseases, particularly in genetic, cardio-metabolic, hepatic infectious, and central nervous system/ocular areas. The company markets several products, including ONPATTRO, which treats polyneuropathy associated with hereditary transthyretin-mediated amyloidosis, and GIVLAARI, designed for adults with acute hepatic porphyria. Alnylam is also advancing other investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company collaborates with various partners, including Sanofi Genzyme and Dicerna Pharmaceuticals, to enhance its RNAi therapeutic development. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals aims to leverage its scientific foundation to potentially transform the treatment landscape for patients with debilitating diseases.